Publications
Global Cardiology
Janusz Lipiecki, Piotr Kalmucki, Larry E. Miller, Nicolas Durel
July 2026
A single-center extension of the REDUCE FMR trial provides the longest known follow-up for any transcatheter mitral repair therapy.
- Ten-year cardiovascular survival was 66% demonstrating long-term durability and treatment impact in an advanced heart failure population
- Median survival was 5.6 years in an elderly and high-risk FMR population
- Predictors of long-term outcomes included baseline LVEF less than 35% and early heart failure hospitalization
ESC Heart Failure
Holder Priebe-Brämer et al
November 2025
This was a single-centre retrospective study of 204 consecutive patients (age 83 ± 6 years, 68% female, 72% HFrEF) with NYHA class II-IV HF and moderate and moderate-to-severe (grade 2 + or 3+) SMR planned for CMCS implantation between 2021 and 2024.
At 3 months:
- NYHA class improved by ≥1 category in 94% of patients and 98% achieved NYHA class I or II.
- MR decreased by ≥1 grade in 91% of patients, with all patients classified as grade 1+ or 2+ post-procedure.
- Vena contracta width decreased (6.43 ± 0.84 to 3.85 ± 1.19 mm; P < 0.001), and there was a reduction of LA area from 44.4 ± 6.0 to 35.4 ± 5.1 cm2 (P < 0.001).
- Diastolic filling was improved (change in E/E′ ratio from 20.1 ± 5.5 to 14.0 ± 3.8; P < 0.001), systolic pulmonary artery pressure was lower in follow-up (44 ± 11 to 35 ± 9 mm; P < 0.001), and there was also a clinically relevant reduction in median BNP levels from 2849 to 1390 pg/mL (P < 0.001).
- These changes were not different between HFrEF and HFpEF.
Polish Heart Journal
Kałmucki P, Lipiecki J, Siminiak T, et al.
April 2025
A new publication in the Polish Heart Journal confirms the clinical benefits of the Carillon Mitral Contour System in treating functional mitral regurgitation (FMR), with results drawn from three prospective studies: TITAN, TITAN II, and REDUCE-FMR. The combined analysis included 113 patients with symptomatic heart failure (NYHA class II–IV) and moderate-to-severe FMR. All patients were treated with the Carillon device, a percutaneous annuloplasty system designed to reduce mitral regurgitation via the coronary sinus.
Key 1-Year Outcomes:
- Mitral Regurgitation Reduction:
- Regurgitant Volume (RV) ↓ 10.5 mL
- Effective Regurgitant Orifice Area (EROA) ↓ 0.06 cm²
- Vena Contracta Width ↓ 0.16 mm
- Reverse Remodeling Indicators:
- LV End-Diastolic Volume (LVEDV) ↓ 15.2 mL
- LV End-Systolic Volume (LVESV) ↓ 13.7 mL
- Ejection Fraction (LVEF) ↑ 1.8%
- Mitral Annular Area ↓ 1.0 cm²
- Functional Improvement:
- NYHA class improved by ≥1 in 68% of patients
- 6-minute walk distance ↑ 51 meters
- KCCQ Quality of Life score ↑ 11.6 points
